2024 EULAR conference: Sparrow Pharmaceuticals presents Phase 2 data on Clofutriben (SPI-62) & prednisolone for polymyalgia rheumatica.
Sparrow Pharmaceuticals presented data from a Phase 2 trial of Clofutriben (SPI-62) and prednisolone in patients with polymyalgia rheumatica (PMR) at the 2024 European League Against Rheumatism (EULAR) conference. The trial combines HSD-1 inhibitor SPI-62 with prednisolone, a corticosteroid, to treat PMR.
June 15, 2024
3 Articles